Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions

To investigate the effects of fimasartan on nonalcoholic fatty liver disease in hyperlipidemic and hypertensive conditions, the levels of biomarkers related to fatty acid metabolism were determined in HepG2 and differentiated 3T3-L1 cells treated by high fatty acid and liver and visceral fat tissue...

Full description

Bibliographic Details
Main Authors:	Yong-Jik Lee, Yoo-Na Jang, Yoon-Mi Han, Hyun-Min Kim, Jong-Min Jeong, Hong Seog Seo
Format:	Article
Language:	English
Published:	Hindawi Limited 2017-01-01
Series:	PPAR Research
Online Access:	http://dx.doi.org/10.1155/2017/8048720

Similar Items

Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice
by: Yong-Jik Lee, et al.
Published: (2017-01-01)

Corrigendum to “Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice”
by: Yong-Jik Lee, et al.
Published: (2019-01-01)

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
by: Yoon-Mi Han, et al.
Published: (2020-01-01)

Stimulation of Alpha1-Adrenergic Receptor Ameliorates Cellular Functions of Multiorgans beyond Vasomotion through PPARδ
by: Yong-Jik Lee, et al.
Published: (2020-01-01)

6-Gingerol Normalizes the Expression of Biomarkers Related to Hypertension via PPARδ in HUVECs, HEK293, and Differentiated 3T3-L1 Cells
by: Yong-Jik Lee, et al.
Published: (2018-01-01)

Aster glehni Extract Containing Caffeoylquinic Compounds Protects Human Keratinocytes through the TRPV4-PPARδ-AMPK Pathway
by: Yong-Jik Lee, et al.
Published: (2018-01-01)

Association of nonalcoholic fatty liver disease with the severity of hyperlipidemic acute pancreatitis
by: MEI Pei
Published: (2021-01-01)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
by: Rhee MY, et al.
Published: (2015-06-01)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
by: Hailian Quan, et al.
Published: (2020-11-01)

Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster.
by: Wei Chen, et al.
Published: (2014-01-01)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
by: Gu N, et al.
Published: (2016-04-01)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
by: Kang WY, et al.
Published: (2018-10-01)

An ethanol extract of Artemisia iwayomogi activates PPARδ leading to activation of fatty acid oxidation in skeletal muscle.
by: Si Young Cho, et al.
Published: (2012-01-01)

Fimasartan for Remodeling after Myocardial Infarction
by: Byung-Kwan Lim, et al.
Published: (2019-03-01)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
by: Min-gu Kang, et al.
Published: (2019-07-01)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
by: Choi Y, et al.
Published: (2018-07-01)

Fatty acids regulate perilipin5 in muscle by activating PPARδ[S]
by: Christian Bindesb⊘ll, et al.
Published: (2013-07-01)

Fimasartan: A new armament to fight hypertension
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Association Between Anxiety and Depression and Nonalcoholic Fatty Liver Disease
by: Ji Min Choi, et al.
Published: (2021-01-01)

Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain
by: Chi Kyung Kim, et al.
Published: (2015-01-01)

Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
by: Naeun Choi, et al.
Published: (2019-04-01)

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study.
by: Eun Joo Cho, et al.
Published: (2019-01-01)

NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?
by: Gerardo G. Mackenzie, et al.
Published: (2008-01-01)

Berberine Ameliorates Brain Inflammation in Poloxamer 407-Induced Hyperlipidemic Rats
by: Mia Kim, et al.
Published: (2019-11-01)

PPAR-δ in Vascular Pathophysiology
by: Nanping Wang
Published: (2008-01-01)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
by: Kang WY, et al.
Published: (2020-05-01)

Association between PPARγ gene rs3856806 polymorphism and nonalcoholic fatty liver disease
by: XU Xin, et al.
Published: (2015-07-01)

Ginseng Saponin Enriched in Rh1 and Rg2 Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Inflammasome Activation
by: Feng Wang, et al.
Published: (2021-03-01)

Silymarin Ameliorates Acrylamide-Induced Hyperlipidemic Cardiomyopathy in Male Rats
by: Ashraf M. Abdel-Moneim, et al.
Published: (2019-01-01)

PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
by: Robert I. Glazer, et al.
Published: (2008-01-01)

The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study
by: Goh Eun Chung, et al.
Published: (2020-10-01)

Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo
by: Larry G. Higgins, et al.
Published: (2012-01-01)

Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease
by: Goh Eun Chung, et al.
Published: (2019-06-01)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
by: Jiayao Yang, et al.
Published: (2020-01-01)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
by: Yun-liang Wang, et al.
Published: (2015-01-01)

Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease[S]
by: Matthew C. Wheeler, et al.
Published: (2014-08-01)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
by: Luis A. Videla, et al.
Published: (2012-01-01)

The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease
by: Goh Eun Chung, et al.
Published: (2016-03-01)

Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study.
by: Jeong Bae Park, et al.
Published: (2017-01-01)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
by: Tae Hwan Kim, et al.
Published: (2018-10-01)